Technology | July 22, 2014

IBA Receives FDA Approval of New Compact Gantry, Clearing Way for ProteusONE

July 22, 2014 — IBA (Ion Beam Applications SA) announced it has received marketing authorization from the U.S. Food and Drug Administration (FDA) for its compact gantry beam line. IBA anticipates this regulatory approval will intensify the international interest in ProteusONE, IBA’s next-generation proton therapy compact system.

ProteusONE is IBA’s single-room proton therapy system that is smaller, less expensive, faster to install and encompasses the latest in targeted proton therapy technologies, including intensity-modulated proton therapy (IMPT). IBA created the ProteusONE system to allow more patients access to proton therapy globally and has already sold five systems in Shreveport, La.; Nice, France; Taiwan; and two in Japan.

“We are delighted to have received marketing authorization from the FDA for the ProteusONE compact gantry. This is an exciting milestone for our customers in North America, where the cost of healthcare is a major focus. The ProteusONE aligns with the U.S. healthcare trend of providing the highest quality of cancer treatment possible at the best possible price,” said Olivier Legrain, CEO of IBA. “We are confident that ProteusONE will drive greater momentum in the adoption of this next-generation targeted cancer treatment internationally. The approval reaffirms our world-leading position in the delivery of highly targeted, safer cancer treatment solutions. We very much look forward to the first patients at the Willis-Knighton Cancer Center [in Shreveport] benefitting from our compact proton therapy offering later this year.”

Added Lane R. Rosen, M.D., director of radiation oncology at the Willis-Knighton Cancer Centre: “We are very excited to have IMPT become an available option for our patients. The complete clearance of the ProteusONE system, installed at Willis-Knighton, is yet another milestone demonstrating how IBA and WKCC partner for progress.”

ProteusONE is the brand name of a new configuration of the Proteus 235.

For more information:

Related Content

New Prostate Cancer Radiotherapy Technique Aims to Preserve Sexual Function
News | Radiation Therapy | June 18, 2018
A multicenter clinical trial being led by UT Southwestern physicians is testing a technique for sparing nerve bundles...
Elekta Unity High-Field MR-Linac Receives CE Mark
News | Image Guided Radiation Therapy (IGRT) | June 18, 2018
Elekta announced that its Elekta Unity magnetic resonance radiation therapy (MR/RT) system has received CE mark,...
Washington University in St. Louis Begins Clinical Treatments With ViewRay MRIdian Linac
News | Image Guided Radiation Therapy (IGRT) | June 14, 2018
June 14, 2018 — The Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in S
Accuray TomoTherapy System Beneficial in Two Total Body Irradiation Studies
News | Radiation Therapy | June 13, 2018
Recently published data from two new studies demonstrate the benefits of Accuray’s TomoTherapy System in the delivery...
IsoRay Funding Brain Cancer Treatment Research With Ochsner Clinic Foundation
News | Brachytherapy Systems | June 12, 2018
IsoRay Inc. announced the initiation of research funding for brain cancer treatment to Ochsner Clinic Foundation, a not...
News | Brachytherapy Systems | June 07, 2018
IsoRay Inc. announced the upcoming release of its Build-Blu delivery system for real-time prostate brachytherapy.
Raysearch RayStation
Feature | Radiation Therapy | June 05, 2018 | By Melinda Taschetta-Millane
Treatment planning systems are at the heart of r...
Beaumont Researchers Invent New Mode of Proton Treatment for Lung Cancer
News | Proton Therapy | May 31, 2018
Members of Beaumont Health’s proton therapy team presented research on a new treatment for patients with lung cancer at...
More Than 60 Percent of Patients Seeking Proton Therapy Initially Denied Coverage
News | Proton Therapy | May 25, 2018
The Alliance for Proton Therapy Access has released a national report revealing the heavy emotional and financial...
News | Treatment Planning | May 24, 2018
Daniela Schmitt, Ph.D., took top honors in the overall category of the 2018 TROG Plan Study: Stereotactic Radiosurgery...
Overlay Init